Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Luisa Paccagnella
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Cancer
Cancer Research
Oncology
Safety, Tolerability, and Pharmacokinetics of the Anti-Igf-1r Monoclonal Antibody Figitumumab in Patients With Refractory Adrenocortical Carcinoma
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Related publications
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Advances in Therapy
Medicine
Pharmacology
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Pediatric Blood and Cancer
Oncology
Child Health
Hematology
Perinatology
Medicine
Pediatrics
Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn146 - Inotuzumab Ozogamicin in Patients With Relapsed or Refractory (R/R) Acute Lymphocytic Leukemia (All): Establishing a Value-Based Cost – Preliminary Results
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Feasibility of Allografting in Patients With Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Assessment of Clinical Immunogenicity of Inotuzumab Ozogamicin in Patients With Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
AAPS Open
High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902
Leukemia Research
Cancer Research
Oncology
Hematology
